Nuo Therapeutics IncOTCQB:AURX
- LAST PRICE0.8000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.8000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nuo Therapeutics Inc | 33.9M | -9.6x | --- |
Viracta Therapeutics Inc | 33.6M | -0.6x | --- |
Janone Inc | 34.1M | -1.1x | --- |
QSAM Biosciences Inc | 35.8M | -5.1x | --- |
Acurx Pharmaceuticals Inc | 31.7M | -1.8x | --- |
Brainstorm Cell Therapeutics Inc | 36.4M | -1.3x | --- |
Company Information
Nuo Therapeutics, Inc. is a regenerative therapies company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. Its flagship product, Aurix, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. The Company’s commercial offering consists of point of care technology for the safe and effective separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix (the Aurix System), which produces a platelet rich plasma (PRP) gel at the point of care using the patient’s own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.
Contact Information
- Headquarters
- 8285 EL RIO, SUITE 150HOUSTON, TX, United States 77054
- Phone
- 832-236-9060
- Fax
- 240-499-2690
Executives
- Acting Chief Executive Officer, Acting Chief Financial Officer, Director
- David Jorden
- Chief Operating Officer, Chief Scientific Officer
- Peter Clausen
- Independent Director
- Paul Mintz
- Independent Director
- Scott Pittman
- Independent Director
- C. Eric Winzer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $33.9M |
|---|---|
Revenue (TTM) | $485.5K |
Shares Outstanding | 42.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.15 |
EPS | $-0.08 |
Book Value | $0.05 |
P/E Ratio | -9.6x |
Price/Sales (TTM) | 69.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -716.64% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
